Even in case if Aldo fails to outperform dox, it should be approved due to zero cardiac toxicity IMO
If it underperforms dox (highly unlikely), pure bad luck.
If it outperforms dox, I expect a value close to what Celgene paid for Abraxane ($2.9 ban) which should be equal to 20-25$ for CYTR.
Sentiment: Strong Buy
You guys don't even read the PR thoroughly? The reason for the partial halt is mentioned.
No reason for death as it is not caused by Aldoxorubicin so stop guessing.
Eli Lilly? You probably have said that 100 times but what is the connection between CytRx and Lilly ? Would you please clarify?
Steve: Not a penny under $50 John.
(John throws the phone in the dustbin)
Steve: John! John? Are you there?
Slide No. 25 October presentation
Note that Fc-Tubulysin EC1456 is curative at half the dose of Vintafolide (1 μmol/kg vs 2 μmol/kg) in preclinical resistant models. Vintafolide is nowhere near to what FC-Tubulysin does.
and the fact is : we are into 3rd cohort of Phase 1 which is near to Vintafolide dose, so its logical to expect ~ 4x more efficacy (doesn't happen in reality but looks very promising with no Dose Limiting Toxicity in first 2 cohorts)
Are you from Sierra World Equity Review ?
If yes, don't ask me how do I know. Any one can Google it out.
If no, better post the source , because there is no agreement with Eli Lilly.
I don't think their patents can block other companies from pursuing folate-drug conjugates. There are plenty of modifications one can do on this platform and ECYT can't patent them all. As per ECYT, the work on folate conjugates started in 1980s so you can't expect very broad patents being granted in 2010s.
Will look at diagnostic agents other companies are using and will get back to you.
yes it's possible to deliver many drugs with folate. But effectiveness of those SMDC will be dependent on multiple factors. Molecular size, stereo-chemistry, stability in plasma, ability to be cleaved inside tumor cells etc. etc. etc.
For your info, few years ago, even before ECYT went public, the giant Bristol Myers Squibb in-licensed ECYT's SMDC platform around 2005. They probably tried to attach 2 molecules (i am not sure) to folate but stopped development in phase II due to low stability in blood/plasma (meaning the drug-folate complex gets cleaved before reaching to the cancer cells).
ECYT was however able to achieve 99% stability in plasma years later (you may still find it mentioned in their recent presentations)
The important thing to note is, we had two partners both BPs at various point of time in the journey of evolving SMDC platform. So, though its not visible to retail investors, BPs always have been circling around ECYT, and they still are. What does $120mn upfront payment from Merck tell you? The partnering process was highly (HIGHLY) competitive and Merck had to outbid other parties to get their hands on what seemed to be the best in class anticancer drug in PII (PRECEDENT trial 2011).
I have no doubt there are multiple parties still wanting to shake hands with ECYT but probably this is not the right time for ECYT as it sits on a cash-pile (thanks to Merck).
Other drugs/companies working/have been working on folate targeting
Farletuzumab (failed P3): Eisai /Morphotek
GALE-301 (Folate Binding Protein) (In Phase 1): Galena Biopharma
Bi-specific Anti-CD3 X Folate: Ambrx
Hope this helps ;)
'your fears are unjustified'.
i am clueless how do you reached to the conclusion that i am feared.
I said i am shocked, not feared (See the title of this thread)
In fact I am long CYTRx. But yes, I don't feel comfortable.
Aldo (yes Aldo) took us from $2 to $6.
Management's DTG connection brought us back from $6 to $2.
So better be cautious. They can do it again (if they are not feared by SEC so far)
I don't if they got richer or not. Doesn't matter if they sold or not. (they apparently haven't been able to sell yet, thanks to Mr. Pearson)
I never had CLDX.
I don't think this is a year old info. Probably you are referring to the exposed connection with Dream Team Group.
IR firm guy trading on insider info from CYTRx is new to me.
I too am here for Aldo but am cautious coz this management took us from $6 to sub $2.5
And kind of comments Mr. Kriegsman is making (not interested in partners !) makes me nervous about my investment in this company.
Fear mongering tactic? Call it whatever you want. I call it truth. And it speaks volumes about the management.
If a third party IR guy is able to take illegal advantage of the situation, why it's hard for you to believe in the theory that these people traded on insider knowledge ?
Stating the truth doesn't and shouldn't mean I am short / I don't understand biotech.
I am not Avi.
I am long CYTRx.
Don't be ignorant and neglect the truth.
It's not about doing something out of ordinary. And do you want to mean that insider trading is ordinary and should be accepted and no one should point a finger towards that ?
No one goes to jail? Huh.
Google : pharma executive jail prison insider trading
If you don't find at least examples, let me know, I will do it for you.
Raw data? Agree. But can you read again what SEC is sayin? The IR guy was aware of the FAVORABLE results. We can't think of CYTRx providing a draft PR based on raw data. Possibly the final PR was ready. Why it wasn't released immediately? The answer to me is clear.
I am not AVI
I am long Cytrx coz of Aldoxo.
"19. CytRx Corporation (“CytRx,” Ticker Symbol: CYTR) is a Delaware corporation headquartered in Los Angeles, California. At all relevant times, CytRx’s common stock was registered with the Commission pursuant to Section 12(b) of the Exchange Act and traded on the NASDAQ. CytRx specializes in oncology research and development and is developing a modified chemotherapeutic agent. On the morning of December 11, 2013, CytRx announced that its potential cancer treatment had outperformed an established chemotherapy in mid-stage testing on patients with soft-tissue sarcoma. CytRx’s stock rose sharply that day to close 68% higher than its close the day before the announcement. IR Firm A provided services to CytRx in connection with this announcement and knew of the favorable clinical trial results at least one week before they were announced to the public."
You can Google some part of above text to see the original complaint.
Now did you notice this: "..IR Firm A provided services to CytRx in connection with this announcement and knew of the favorable clinical trial results ! at least one week before ! they were announced to the public.."
1. SEC says IR firm (and so the Cytrx officials themselves) knew of positive the results at least 7 days in advance .
2. The PR was announced on 11th December.
3. Now look at the options awarded to CYTRx insiders just 1-2 day prior to announcement=9th-10th December
Hate to say this, but AF had a legit article on this matter titled: CytRx Directors Are $3M Richer With Well-Timed Stock Option Grants (plz google , cant post the link, thanks to yahoo)
Again, not casting doubts on Aldoxo, but i m convinced these guys are crooks.
why would it rally? I see no catalysts in near term (month end). What am I missing?